MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer
<p>Abstract</p> <p>Background</p> <p>Hormone therapy is the standard of care for newly diagnosed or recurrent prostate cancers. It uses anti-androgen agents, castration, or both to eliminate cancer promoting effect of testicular androgen. The p53 tumor suppressor contro...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2011-05-01
|
| Series: | Molecular Cancer |
| Online Access: | http://www.molecular-cancer.com/content/10/1/49 |